Financial Survey: Genmab A/S (GMAB) vs. Its Peers

Share on StockTwits

Genmab A/S (NASDAQ: GMAB) is one of 596 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Genmab A/S to related companies based on the strength of its profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Genmab A/S and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genmab A/S 42.39% 16.26% 15.23%
Genmab A/S Competitors -2,502.83% -853.69% -32.24%

Earnings and Valuation

This table compares Genmab A/S and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Genmab A/S $479.18 million $233.19 million 6.26
Genmab A/S Competitors $2.11 billion $223.53 million -3.39

Genmab A/S’s rivals have higher revenue, but lower earnings than Genmab A/S. Genmab A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for Genmab A/S and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S 0 0 6 0 3.00
Genmab A/S Competitors 5791 15771 31486 1210 2.52

Genmab A/S currently has a consensus price target of $23.67, suggesting a potential upside of 0.54%. As a group, “Pharmaceutical preparations” companies have a potential upside of 48.03%. Given Genmab A/S’s rivals higher possible upside, analysts clearly believe Genmab A/S has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

19.6% of Genmab A/S shares are held by institutional investors. Comparatively, 45.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Genmab A/S beats its rivals on 7 of the 12 factors compared.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.